Prescription Demand: Total LINZESS prescription demand in the fourth quarter of 2023 was 50 million LINZESS capsules, a 10% increase compared to the fourth quarter of 2022, per IQVIA. Total ...
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
– 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; ...
Ironwood Pharmaceuticals (NASDAQ:IRWD) delivered a robust first quarter 2026 performance that exceeded Wall Street expectations, according to the company’s investor presentation released on May 7, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results